As Chinese biotech companies have faced a cash crunch at home, it has become necessary for them to look abroad for partnering opportunities to advance their assets through the clinic. This trend has led Johnson & Johnson to take an interest in linking arms with firms in China, albeit mindful of the current geopolitical climate, said Nauman Shah, global head of business development at Johnson & Johnson Innovation, at a 10 February fireside chat at the BIO CEO & Investor Conference.
Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
More from BIO
• By
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
• By
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.
• By
Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.
• By
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.